AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31615456 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 200
Study 31615456 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 200
Study 28177728 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily light physical activity for a minimum of 30 minutes starting a maximum of 30 minutes after a meal for 12 weeks
Number of subjects: 56
Study 28177728 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained their usual lifestyle
Number of subjects: 56
Study 25547711 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 1008
Study 25547711 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 1008
Study 25547711 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine‐extended release
Number of subjects: 1008
Study 25547711 — intervention group
Group type: COMPARATOR
Intervention: cognitive tests
Number of subjects: 1008
Study 23442284 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 6
Study 23442284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 21489062 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus on self
Number of subjects: 30
Study 21489062 — intervention group
Group type: COMPARATOR
Intervention: External focus on surroundings
Number of subjects: 30
Study 21489062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of bodily sensations
Number of subjects: 30
Study 19430829 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic procedure (n = 52)
Number of subjects: 109
Study 19430829 — intervention group
Group type: COMPARATOR
Intervention: Open procedure (n = 49)
Number of subjects: 109
Study 16563900 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose infusion (1 L) prior to catheterization
Number of subjects: 49
Study 16563900 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dextrose infusion)
Number of subjects: 49
Study 15560689 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of Follitropin beta
Number of subjects: 60
Study 15560689 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of Follitropin beta
Number of subjects: 60
Study 11746615 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg t.i.d. (possible increase to 200 mg t.i.d.)
Number of subjects: 203
Study 11746615 — intervention group
Group type: COMPARATOR
Intervention: pergolide titrated to a maximum dose of 5 mg/day (mean final dose 2.2 mg/day)
Number of subjects: 203
Study 9431631 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and patient education program during pregnancy
Number of subjects: 362
Study 9431631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 362
Study 8374232 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE VISTA bifocal IOL (TV)
Number of subjects: 33
Study 8374232 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M diffractive bifocal IOL (3M)
Number of subjects: 33
Study 8374232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordan Aspheric Varifocal Silicone IOL (VF)
Number of subjects: 33
Study 2442506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10-40 mg daily)
Number of subjects: 54
Study 2442506 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (40-80 mg three times daily)
Number of subjects: 54
Study 2442506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (long-acting form, 20-80 mg daily)
Number of subjects: 54
Study 2442506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31618099 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Entitlement Scale (PES)
Number of subjects: 523
Study 31618099 — intervention group
Group type: EXPERIMENTAL
Intervention: PES-G (grandiose-based entitlement)
Number of subjects: 523
Study 31618099 — intervention group
Group type: EXPERIMENTAL
Intervention: PES-V (vulnerable-based entitlement)
Number of subjects: 523
Study 29846661 — intervention group
Group type: EXPERIMENTAL
Intervention: Optia
Number of subjects: 0
Study 29846661 — intervention group
Group type: COMPARATOR
Intervention: COBE
Number of subjects: 0
Study 28315068 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m2 (nP150)
Number of subjects: 1207
Study 28315068 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 125 mg/m2 (nP125)
Number of subjects: 1207
Study 28315068 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel 80 mg/m2 (P80)
Number of subjects: 1207
Study 26508749 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 386
Study 26508749 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 386
Study 24216771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinna cue‐preserving microphone position
Number of subjects: 17
Study 24216771 — intervention group
Group type: COMPARATOR
Intervention: Microphone position not preserving pinna cues
Number of subjects: 17
Study 21358428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 18
Study 21358428 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 18
Study 18089850 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: 6 weeks of daily prednisone and weekly vinblastine followed by 18 weeks of daily 6‐mercaptopurine with vinblastine/prednisone pulses
Number of subjects: 193
Study 18089850 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Etoposide added to the regimen of Arm A
Number of subjects: 193
Study 18089850 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B
Number of subjects: 193
Study 18089850 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 193
Study 18089850 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (intensified treatment)
Number of subjects: 193
Study 18089850 — intervention group
Group type: COMPARATOR
Intervention: Arm A LCH‐I
Number of subjects: 193
Study 16514225 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml/kg of 25 microg/kg butorphanol in combination with 0.25% bupivacaine
Number of subjects: 60
Study 16514225 — intervention group
Group type: COMPARATOR
Intervention: 1 ml/kg of 0.25% bupivacaine
Number of subjects: 60
Study 16514225 — intervention group
Group type: COMPARATOR
Intervention: 1 ml/kg of 25 microg/kg butorphanol diluted in normal saline
Number of subjects: 60
Study 14606508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice hockey training
Number of subjects: 68
Study 14606508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of ice hockey training
Number of subjects: 68
Study 14606508 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued ice hockey training
Number of subjects: 68
Study 14606508 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 10790348 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 20 ppm nitric oxide (NO)
Number of subjects: 14
Study 9292747 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy
Number of subjects: 130
Study 9292747 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 130
Study 9292747 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy with sucralfate
Number of subjects: 130
Study 9292747 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy without sucralfate
Number of subjects: 130
Study 8347966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 395
Study 8347966 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 395
Study 8347966 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment
Number of subjects: 395
Study 3510014 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (2 g for eight doses)
Number of subjects: 158
Study 3510014 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation of uterus and peritoneum with 2 g of antibiotic
Number of subjects: 158
Study 3510014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous and irrigation
Number of subjects: 158
Study 3510014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 158
Study 30646931 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB-guided method (F)
Number of subjects: 50
Study 30646931 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (C)
Number of subjects: 50
Study 28703859 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 or 38 mg iron for 60 days
Number of subjects: 692
Study 28703859 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational letter advising low ferritin levels
Number of subjects: 692
Study 28703859 — intervention group
Group type: COMPARATOR
Intervention: Educational letter lacking specific recommendation
Number of subjects: 692
Study 28703859 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron pills
Number of subjects: 692
Study 25731946 — intervention group
Group type: EXPERIMENTAL
Intervention: Module-based training with skills-lab course followed by 20 supervised Lichtenstein hernia repairs
Number of subjects: 18
Study 25731946 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 18
Study 23905375 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) at 1.5 mL/kg (dissolved in 250 mL 5% glucose solution), administered intravenously once daily for 5 days before operation.
Number of subjects: 30
Study 23905375 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group), equal dose to SFI group, administered 30 min before anesthesia induction.
Number of subjects: 30
Study 23905375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups assessed with mini-mental state examination (MMSE) scale.
Number of subjects: 30
Study 21568982 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 50
Study 21568982 — intervention group
Group type: COMPARATOR
Intervention: LMA-Unique
Number of subjects: 50
Study 21568982 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel (mild subgroup)
Number of subjects: 50
Study 21568982 — intervention group
Group type: COMPARATOR
Intervention: LMA-Unique (mild subgroup)
Number of subjects: 50
Study 21568982 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel (moderate subgroup)
Number of subjects: 50
Study 21568982 — intervention group
Group type: COMPARATOR
Intervention: LMA-Unique (moderate subgroup)
Number of subjects: 50
Study 19123002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m² on a 21-day schedule (group A)
Number of subjects: 50
Study 19123002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m² on a 7-day schedule (group B)
Number of subjects: 50
Study 16820373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast 100 mg, 3 times daily (T(+) group)
Number of subjects: 20
Study 16820373 — intervention group
Group type: COMPARATOR
Intervention: Control group (T(‐) group)
Number of subjects: 20
Study 16820373 — intervention group
Group type: COMPARATOR
Intervention: Tranilast treatment vs Control
Number of subjects: 20
Study 15585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (40 mg or 0.01 ml/kg, subcutaneous injection, every 12 hours)
Number of subjects: 17
Study 15585141 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 17
Study 11027423 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-Cis retinoic acid at a dose of 0.75 mg/kg/day
Number of subjects: 175
Study 11027423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 9408562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency fore-and-aft vibration with a 4-point harness
Number of subjects: 12
Study 9408562 — intervention group
Group type: COMPARATOR
Intervention: Low frequency fore-and-aft vibration without a harness
Number of subjects: 12
Study 9408562 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequencies of lateral vibration
Number of subjects: 12
Study 9408562 — intervention group
Group type: EXPERIMENTAL
Intervention: Random vibration
Number of subjects: 12
Study 9408562 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal vibration in the range 1 to 4 Hz
Number of subjects: 12
Study 8436775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg oral calcium
Number of subjects: 0
Study 8436775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2944687 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture
Number of subjects: 0
Study 2944687 — intervention group
Group type: COMPARATOR
Intervention: Upright posture
Number of subjects: 0
Study 2944687 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation of antishock trousers
Number of subjects: 0
Study 29186389 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg orally twice daily for 10 days
Number of subjects: 100
Study 29186389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29186389 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 100
Study 26994634 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive medications (any)
Number of subjects: 947
Study 26994634 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid pain medications
Number of subjects: 947
Study 26994634 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid psychotropic medications
Number of subjects: 947
Study 24630293 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port access (SPA) laparoscopic ovarian cystectomy
Number of subjects: 87
Study 24630293 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-port access (TPA) laparoscopic ovarian cystectomy
Number of subjects: 87
Study 24630293 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-port access (FPA) laparoscopic ovarian cystectomy
Number of subjects: 87
Study 22795280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading/90 mg twice daily)
Number of subjects: 76
Study 22795280 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg loading/75 mg daily)
Number of subjects: 76
Study 20454968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 4954
Study 17295559 — intervention group
Group type: EXPERIMENTAL
Intervention: Penn Resiliency Program (PRP)
Number of subjects: 697
Study 17295559 — intervention group
Group type: COMPARATOR
Intervention: Penn Enhancement Program (PEP)
Number of subjects: 697
Study 17295559 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 697
Study 15764959 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg weekly for 48 weeks) + vitamin D (400 IU daily) + calcium (1000 mg daily)
Number of subjects: 31
Study 15764959 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (400 IU daily) + calcium (1000 mg daily)
Number of subjects: 31
Study 11868620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodefense rape story
Number of subjects: 0
Study 11868620 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprosecution rape story
Number of subjects: 0
Study 11868620 — intervention group
Group type: COMPARATOR
Intervention: Nonrape story
Number of subjects: 0
Study 10661043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated employees
Number of subjects: 1710
Study 10661043 — intervention group
Group type: COMPARATOR
Intervention: Nonvaccinated employees
Number of subjects: 1710
Study 10661043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost savings from vaccination
Number of subjects: 1710
Study 7850589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine hydrochloride 10 mg by mouth
Number of subjects: 5521
Study 7850589 — intervention group
Group type: COMPARATOR
Intervention: Monitoring without treatment
Number of subjects: 5521
Study 1803833 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 90
Study 1803833 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 90
Study 1803833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg/kg
Number of subjects: 90
Study 1803833 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil 1 mg
Number of subjects: 90
Study 1803833 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil 0.5 mg
Number of subjects: 90
Study 1803833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 6851262 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin and cloxacillin
Number of subjects: 36
Study 6851262 — intervention group
Group type: COMPARATOR
Intervention: cephalothin
Number of subjects: 36
Study 31918584 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIP intervention group (N = 60)
Number of subjects: 120
Study 31918584 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 60)
Number of subjects: 120
Study 31385881 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU recovery program
Number of subjects: 232
Study 31385881 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 232
Study 29666071 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus-eluting stents
Number of subjects: 1037
Study 29666071 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1037
Study 29666071 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated BNP levels
Number of subjects: 1037
Study 29666071 — intervention group
Group type: COMPARATOR
Intervention: Normal BNP levels
Number of subjects: 1037
Study 29666071 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI versus CABG in patients with elevated BNP
Number of subjects: 1037
Study 29666071 — intervention group
Group type: COMPARATOR
Intervention: PCI versus CABG in patients with normal BNP
Number of subjects: 1037
Study 23828124 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise group (n=15)
Number of subjects: 46
Study 23828124 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=15)
Number of subjects: 46
Study 23828124 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (n=16)
Number of subjects: 46
Study 20878837 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor physical health (bottom two quintiles)
Number of subjects: 2967
Study 20878837 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater hostility
Number of subjects: 2967
Study 19150206 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Men Are Safe (REMAS; five sessions containing information, motivational exercises, and skills training)
Number of subjects: 590
Study 19150206 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Men Are Safe (REMAS; five sessions)
Number of subjects: 590
Study 19150206 — intervention group
Group type: COMPARATOR
Intervention: HIV education (HIV‐Ed; one session containing HIV prevention information)
Number of subjects: 590
Study 17381398 — intervention group
Group type: EXPERIMENTAL
Intervention: Open management of the abdomen (group A)
Number of subjects: 40
Study 17381398 — intervention group
Group type: COMPARATOR
Intervention: Closed management of the abdomen (group B)
Number of subjects: 40
Study 15456079 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a 180 microg once weekly
Number of subjects: 22
Study 15456079 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alpha-2b 1.0 microg/kg once weekly
Number of subjects: 22
Study 11373253 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of alcohol per day (as beer, red wine or spirits) for 6 weeks
Number of subjects: 60
Study 11373253 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 60
Study 9170763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) including detailed explanation of obsessive thoughts, exposure, response prevention, cognitive restructuring, and relapse prevention.
Number of subjects: 29
Study 9170763 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list condition (Control)
Number of subjects: 29
Study 8190534 — intervention group
Group type: EXPERIMENTAL
Intervention: High titer Edmonston-Zagreb measles vaccine
Number of subjects: 0
Study 8190534 — intervention group
Group type: COMPARATOR
Intervention: Medium titer Edmonston-Zagreb measles vaccine
Number of subjects: 0
Study 8190534 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 3296979 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 130
Study 3296979 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with amiloride
Number of subjects: 130
Study 29189583 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training only (S)
Number of subjects: 245
Study 29189583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training only (A)
Number of subjects: 245
Study 29189583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasession aerobic and strength training (AS)
Number of subjects: 245
Study 29189583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasession strength and aerobic training (SA)
Number of subjects: 245
Study 29189583 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training performed in different sessions (CT)
Number of subjects: 245
Study 29189583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training regimen) (C)
Number of subjects: 245
Study 29781785 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% watermelon juice
Number of subjects: 0
Study 29781785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27155142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress induced by the Trier Social Stress Test
Number of subjects: 24
Study 27155142 — intervention group
Group type: COMPARATOR
Intervention: Non-stress condition (control)
Number of subjects: 24
Study 24763755 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids administered within 2 to 3 days of antibiotic therapy
Number of subjects: 0
Study 24763755 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids administered after 4 or more days of antibiotic therapy
Number of subjects: 0
Study 24763755 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids administered earlier in patients with non-Nocardia keratitis
Number of subjects: 0